Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?

Which neoadjuvant treatment do you generally use for a patient with locally advanced (T3 lesion), ER-negative, HER2-positive breast cancer who desires breast conservation?

Tx 45 yo w/ 0.8-cm node-neg, ER-neg/HER2+ early BC? Tx 70 yo w/ 1 pos node, ER-neg/HER2+ early BC?

Which systemic treatment do you generally use for a 45-year-old patient with node-negative, ER-negative, HER2-positive early breast cancer with a 0.8-cm tumor?

Which systemic treatment do you generally use for a 70-year-old woman with ER-negative, HER2-positive early breast cancer and 1 positive node?

60 yo, 2.1-cm node-neg IDC, ER-neg/HER2+, adj AC TH: Tx if lumpectomy bed recurrence 2 y later and NED?

How often would you use pertuzumab combined w/ trastuzumab/chemo in the neoadjuvant setting?

With approval of pertuzumab in the neoadjuvant setting, how often do you think you would use it in combination with trastuzumab/chemotherapy when using neoadjuvant treatment for HER2-positive disease?

Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?

Which neoadjuvant treatment do you generally use for a patient with locally advanced (T3 lesion), ER-negative, HER2-positive breast cancer who desires breast conservation?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, breast/general surgeons and other healthcare practitioners involved in the management of breast cancer.

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed type of cancer in women, with an estimated 234,580 new cases and 40,030 deaths in the United States in 2013. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

Efficacy/tolerability of 2^nd-line aflibercept vs bev beyond PD

How would you compare the efficacy of aflibercept to the use of bevacizumab on disease progression in the second-line setting?

How would you compare the side effects and tolerabilty of aflibercept to the use of bevacizumab on disease progression in the second-line setting?

60 yo with obvious progression within a few months of FOLFOX/bev?

What systemic treatment would you most likely recommend for the following patients:

A 60-year-old patient with asymptomatic mCRC receives FOLFOX/bevacizumab but within a few months experiences obvious disease progression. The tumor is KRAS wild type.

Same as above, but the tumor is KRAS mutant?

75 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

What systemic treatment would you most likely recommend for the following patients:

60 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

What systemic treatment would you most likely recommend for the following patients:

Efficacy/tolerability of 2^nd-line aflibercept vs bev beyond PD

How would you compare the efficacy of aflibercept to the use of bevacizumab on disease progression in the second-line setting?

How would you compare the side effects and tolerabilty of aflibercept to the use of bevacizumab on disease progression in the second-line setting?

60 yo with obvious progression within a few months of FOLFOX/bev?

What systemic treatment would you most likely recommend for the following patients:

A 60-year-old patient with asymptomatic mCRC receives FOLFOX/bevacizumab but within a few months experiences obvious disease progression. The tumor is KRAS wild type.

Same as above, but the tumor is KRAS mutant?

75 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

What systemic treatment would you most likely recommend for the following patients:

60 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

What systemic treatment would you most likely recommend for the following patients: